Phase 2 screening trial in 32 evaluable patients with untreated metastatic pancreatic cancer on gemcitabine, nab-paclitaxel and cisplatin: median PFS 8.5 months with a supervised ketogenic diet vs 6.2 with usual diet (HR 0.53, 95% CI 0.21-1.37; one-sided p=0.096).
RCTn = 32
Jameson et al. A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer